These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1357583)

  • 1. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
    Jellinek T
    Dis Nerv Syst; 1977 May; 38(5):353-5. PubMed ID: 852367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced extrapyramidal side-effects in Egyptian schizophrenic patients.
    Okasha A; El Okbi H; Sadek A; Lotiaf F; Ashour AM
    Egypt J Psychiatry; 1979 Oct; 2(2):191-7. PubMed ID: 45368
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people.
    Kalish SC; Bohn RL; Mogun H; Glynn RJ; Gurwitz JH; Avorn J
    J Am Geriatr Soc; 1995 Sep; 43(9):967-73. PubMed ID: 7657936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Shakuyaku-Kanzo-to on Extrapyramidal Symptoms During Antipsychotic Treatment: A Randomized, Open-Label Study.
    Ota T; Miura I; Kanno-Nozaki K; Hoshino H; Horikoshi S; Fujimori H; Kanno T; Mashiko H; Yabe H
    J Clin Psychopharmacol; 2015 Jun; 35(3):304-7. PubMed ID: 25839338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study.
    Horiguchi J; Nishimatsu O
    Jpn J Psychiatry Neurol; 1992 Sep; 46(3):733-9. PubMed ID: 1362592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
    Chamorro García L
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.
    Hitri A; Craft RB; Sethi R; Sinha D
    Clin Neuropharmacol; 1987 Jun; 10(3):261-71. PubMed ID: 2900683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?
    Manos N; Gkiouzepas J
    Acta Psychiatr Scand; 1981 Jan; 63(1):28-32. PubMed ID: 6112842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia.
    Ungvari GS; Chiu HF; Lam LC; Pang AH; Chung DW; Li SW; Chiu SN; Lum FC; Leung T
    J Clin Psychopharmacol; 1999 Apr; 19(2):141-8. PubMed ID: 10211915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian prescription and extrapyramidal symptoms.
    Grover S; Kulhara P
    Br J Psychiatry; 2006 May; 188():492; author reply 492-3. PubMed ID: 16648544
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal.
    Perenyi A; Gardos G; Samu I; Kallos M; Cole JO
    Clin Neuropharmacol; 1983 Mar; 6(1):55-61. PubMed ID: 6133613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
    Weisbard JJ; Pardo M; Pollack S
    Psychopharmacol Bull; 1997; 33(1):119-22. PubMed ID: 9133762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.